Search

A study conducted in Mexico City examined the incidence of non-alcoholic fatty liver disease (NAFLD) in people living with HIV who were starting antiretroviral therapy. The research found that there was a high incidence of NAFLD in this population, with risk factors including baseline overweight, low HDL-cholesterol, and specific biomarkers at 48 weeks of treatment. The study concluded that these findings highlight the importance of monitoring and managing liver health in individuals with HIV starting antiretroviral therapy. [Extracted from the article]

A recent meta-analysis conducted by Mayo Clinic researchers evaluated the effectiveness of mobile health intervention (mHI) for non-alcoholic fatty liver disease (NAFLD). The study found that mHI, which involves the use of mobile health technologies, significantly reduced weight and liver markers in patients with NAFLD. The findings suggest that mHI could play a crucial role in managing NAFLD and improving patient outcomes. NAFLD is the most common cause of chronic liver disease worldwide, and lifestyle modification is currently the main approach to management. [Extracted from the article]

Researchers at Houston Methodist Hospital have reported new data on the safety and efficacy of a controlled metabolic accelerator called HU6 in treating non-alcoholic fatty liver disease (NAFLD) in individuals with a high body mass index (BMI). The study involved a randomized, double-blind, placebo-controlled trial with participants receiving different doses of HU6 or a placebo for 61 days. The results showed that HU6 led to a significant reduction in liver fat content compared to the placebo group, with no serious adverse events reported. The researchers suggest that HU6 could be a promising treatment option for patients with obesity and NAFLD. [Extracted from the article]

A recent report from Children's Mercy Kansas City provides new insights into non-alcoholic fatty liver disease (NAFLD), which is a leading cause of liver disease in children and adults. The study focused on the potential biomarker leukocyte cell-derived chemotaxin 2 (LECT2) and its correlation with NAFLD in pediatric patients. The researchers found that LECT2 concentrations were significantly elevated in children with NAFLD compared to healthy controls, and it had strong correlations with body mass index (BMI). The study suggests that LECT2 could be a potential diagnostic biomarker for NAFLD and should be further investigated in both pediatric and adult populations. [Extracted from the article]

Keywords: Falls Church; State:Virginia; United States; North and Central America; Alcohol-Induced Diseases and Conditions; Alcoholic Fatty Liver; Alcoholism; Chronic Liver Disease; Digestive System Diseases and Conditions; Fatty Liver; Fatty Liver Disease; Health and Medicine; Hepatology; Liver Diseases and Conditions; Non-Alcoholic Fatty Liver Disease; Non-Alcoholic Steatohepatitis EN Falls Church State:Virginia United States North and Central America Alcohol-Induced Diseases and Conditions Alcoholic Fatty Liver Alcoholism Chronic Liver Disease Digestive System Diseases and Conditions Fatty Liver Fatty Liver Disease Health and Medicine Hepatology Liver Diseases and Conditions Non-Alcoholic Fatty Liver Disease Non-Alcoholic Steatohepatitis 2023 FEB 20 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Current study results on Liver Diseases and Conditions - Non-Alcoholic Fatty Liver Disease have been published. For more information on this research see: Clinical and Patient-reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-alcoholic Steatohepatitis (Nash)/ Non-alcoholic Fatty Liver Disease (Nafld) Registry. [Extracted from the article]